You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

464 Results
Regimen
Cancer Type:
Sarcoma, 
Soft Tissue
Intent: Palliative
Nov 2017
Regimen
Cancer Type:
Genitourinary, 
Testis
Intent: Curative
Mar 2021
Regimen
Intent: Palliative
Funding:
Exceptional Access Program
    trametinib - As monotherapy in patients with BRAF V600 mutation-positive unresectable or metastatic melanoma, according to specific criteria
Jun 2025
Regimen
Cancer Type:
Gynecologic, 
Endometrial, 
Ovary
Intent: Palliative
Funding:
ODB - General Benefit
    tamoxifen
May 2022
Regimen
Cancer Type:
Gynecologic, 
Ovary
Intent: Palliative
Jul 2025
Regimen
Cancer Type:
Sarcoma, 
Desmoid Tumour
Intent: Curative
Funding:
ODB - General Benefit
    tamoxifen
May 2019
Regimen
Cancer Type:
Endocrine, 
Thyroid
Intent: Palliative
Oct 2020
Regimen
Cancer Type:
Gynecologic, 
Uterine Sarcoma, 
Sarcoma, 
Uterine
Intent: Palliative
Nov 2017
Regimen
Cancer Type:
Hematologic, 
Rare Diseases
Intent: Palliative
Funding:
New Drug Funding Program
    Siltuximab - Multicentric Castleman’s Disease (MCD)
Mar 2025
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Myeloid (AML)
Intent: Curative
Jun 2019
Regimen
Cancer Type:
Gynecologic, 
Germ Cell
Intent: Curative
Mar 2021
Regimen
Cancer Type:
Gynecologic, 
Ovary
Intent: Palliative
Funding:
New Drug Funding Program
    Bevacizumab (Biosimilar) for Platinum-Resistant Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Sep 2023

Pages